Lercanidipine Evolugen (Lercanidipine Hydrochloride)

Lercanidipine is a calcium‑channel‑blocking antihypertensive used to manage elevated blood pressure.

• Essential hypertension: reduces both systolic and diastolic blood pressure in primary hypertension.
• Isolated systolic hypertension: helps control elevated systolic pressure, especially in older adults.
• Secondary hypertension (e.g., renovascular): may be incorporated into combination therapy to achieve target blood pressure.

• Lercanidipine selectively blocks L‑type calcium channels on vascular smooth muscle, inhibiting calcium influx. This leads to relaxation of arterial smooth muscle, vasodilation, and a consequent reduction in peripheral vascular resistance, which lowers systemic blood pressure without significant negative inotropic effects.

Lercanidipine is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects

• Headache: mild to moderate intensity.
• Flushing: transient warmth and redness.
• Peripheral edema: swelling of ankles or feet.
• Dizziness or light‑headedness.
• Tachycardia: increased heart rate.
• Fatigue: feeling of tiredness.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, or throat requiring emergency care.
• Severe hypotension: marked drop in blood pressure causing fainting.
• Myocardial infarction: rare occurrence of heart attack.
• Elevated liver enzymes: indication of hepatic stress.
• Severe allergic reaction: rash, itching, or anaphylaxis.
• Cardiac arrhythmia: abnormal heart rhythms.

Before initiating therapy, clinicians should consider several safety factors.

• Blood pressure monitoring: check baseline and follow‑up readings.
• Hepatic impairment: use with caution in patients with liver dysfunction.
• Concomitant antihypertensives: adjust doses to avoid excessive hypotension.
• Heart failure: evaluate for fluid retention risk.
• Gradual discontinuation: taper dose to prevent rebound hypertension.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine may interact with other medicines that affect its metabolism or blood‑pressure‑lowering effect.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels.
• Other calcium‑channel blockers: additive vasodilatory effect can cause severe hypotension.
• Grapefruit juice: can raise drug concentration and risk of adverse events.
• Simultaneous use with other antihypertensives: may lead to excessive blood pressure drop.
• Rifampicin (CYP3A4 inducer): may reduce efficacy.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: monitor heart rate and blood pressure.

• Diuretics: watch for electrolyte disturbances.
• NSAIDs: may blunt antihypertensive response.
• Antidiabetic agents: monitor glucose control as blood pressure changes can affect insulin sensitivity.
• Certain antiretrovirals: assess for altered drug levels.